Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06215677
NA

Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer

Sponsor: Peking Union Medical College Hospital

View on ClinicalTrials.gov

Summary

Due to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can improve the R0 resection rate with preservation of adjacent organs in T4 colon cancer patients with dMMR.

Official title: Efficacy of Neoadjuvant Immunotherapy for T4 Deficient Mismatch Repair (dMMR) Colon Cancer: A Prospective, Single-arm, Phase Ⅱ Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2024-01-01

Completion Date

2030-02-10

Last Updated

2025-09-05

Healthy Volunteers

No

Interventions

DRUG

Camrelizumab

Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.

Locations (2)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Peking Union Medical College Hospital

Beijing, China